. Epigenetically, IDH1-mutant gliomas exhibit a CpG island methylator phenotype (CIMP), characterized by increased global DNA methylation 9 . In the absence of effective treatments, most grade II and III gliomas eventually progress to more aggressive GBMs 10 .
Gliomas represent approximately 30% of all central nervous system tumors and 80% of malignant brain tumors 1 . To understand the molecular mechanisms underlying the malignant progression of low-grade gliomas with mutations in IDH1 (encoding isocitrate dehydrogenase 1), we studied paired tumor samples from 41 patients, comparing highergrade, progressed samples to their lower-grade counterparts. Integrated genomic analyses, including whole-exome sequencing and copy number, gene expression and DNA methylation profiling, demonstrated nonlinear clonal expansion of the original tumors and identified oncogenic pathways driving progression. These include activation of the MYC and RTK-RAS-PI3K pathways and upregulation of the FOXM1- and E2F2-mediated cell cycle transitions, as well as epigenetic silencing of developmental transcription factor genes bound by Polycomb repressive complex 2 in human embryonic stem cells. Our results not only provide mechanistic insight into the genetic and epigenetic mechanisms driving glioma progression but also identify inhibition of the bromodomain and extraterminal (BET) family as a potential therapeutic approach.
Gliomas have traditionally been classified into low-grade versus malignant, high-grade tumors on the basis of cellular density, nuclear atypia, mitotic index and presence of necrosis, defining pathological grades I through IV (ref. 2) . Among these, grade IV glioma, or glioblastoma multiforme (GBM), remains one of the deadliest cancers, with median survival times of only 12.2 to 18.2 months [3] [4] [5] . Although most GBMs are primary and occur de novo, about 20% are secondary, arising through the progression of preexisting lower-grade gliomas of grade II or III (ref. 2) . The genetic and epigenetic landscapes of grade II and III gliomas have been extensively studied [6] [7] [8] . Genetically, 80% harbor neomorphic IDH1 mutations affecting Arg132, which coexist either with TP53 and ATRX mutations along with chromosome 17p loss of heterozygosity (LOH) in astrocytic tumors or with CIC and FUBP1 mutations as well as chromosome 1p and 19q deletions in oligodendroglial tumors [6] [7] [8] . Epigenetically, IDH1-mutant gliomas exhibit a CpG island methylator phenotype (CIMP), characterized by increased global DNA methylation 9 . In the absence of effective treatments, most grade II and III gliomas eventually progress to more aggressive GBMs 10 .
To uncover the molecular mechanisms underlying the malignant transformation of gliomas, we first sequenced the exomes of 41 IDH1-mutant grade II and III gliomas (20 with matching blood DNA samples) obtained at initial diagnosis and their progressed counterparts collected up to 10 years later, reaching 154-fold coverage on average ( Supplementary Fig. 1 and Supplementary Tables 1 and 2 ). We identified a median of 31 and 80 somatic protein-altering mutations in tumors with and without matching normal DNA samples, respectively. Overall, considering all 82 sequenced gliomas, we confirmed frequent mutations in several driver genes previously reported to be mutated in gliomas [6] [7] [8] (Fig. 1a) . We also identified NOTCH1 and NOTCH2 mutations, occurring within sequences encoding the EGF-like domains, consistent with inactivating mutations identified in squamous cell carcinomas 6, [11] [12] [13] [14] (Fig. 1b) . Interestingly, a highly conserved Phe357 residue in EGF-like domain 9 of NOTCH1, near Integrated genomic characterization of IDH1-mutant glioma malignant progression 6 0 VOLUME 48 | NUMBER 1 | JANUARY 2016 Nature GeNetics l e t t e r s the calcium-binding domain, was recurrently altered in four patients 15 ( Fig. 1b) . Additionally, several target genes of NOTCH signaling were downregulated in NOTCH1-and NOTCH2-mutant tumors (Supplementary Fig. 2 ). Lastly, we identified new mutations in FAT receptor genes, including FAT1, FAT2 and FAT3 (Fig. 1a) 16 . Besides coding mutations, we also detected copy number alterations (CNAs), including 1p and 19q deletions in oligodendroglial tumors (q = 5.7 × 10 −16 and 2.0 × 10 −12 , respectively, two-sided Fisher's exact test) and copy-neutral LOH at the TP53 locus on chromosome 17p (q = 1.4 × 10 −7 ) in astrocytic tumors [6] [7] [8] (Fig. 1c,d and Supplementary Fig. 3 ). Of note, deletion of the CDKN2A-CDKN2B tumor-suppressor locus (9p), despite being the most frequent CNA event, occurring in 44% of all tumors analyzed, did not show any enrichment within a particular glioma subtype (q = 0.6) (Fig. 1c,d and Supplementary Fig. 4 ). CCND2  KRAS  FOXM1  EGFR  PDGFRA  MYC  FUBP1  CDKN2C  CIC  ARID1A  TP53  ARID1B  RB1  CDKN1C  FAT2  ARID2  TCF12  PTEN  PBRM1  DICER1  FAT1  ATRX  CDKN1B  MAX  CDKN2A-CDKN2B OLIG2 FBXW7 Figure 1 Genomic landscape of IDH1-mutant gliomas (n = 82 tumors). (a) Recurrently mutated genes. For PIK3R1, PIK3CA, EGFR, MET, NF2 and MAX, only data for known hotspot mutations are plotted. Recurrently mutated genes, which are grouped on the basis of molecular pathways, are shown on the left. Their mutation frequencies in grade II tumors and in grade III and IV tumors are shown on the right. Each tumor's clinicopathological characteristics are shown at the top, and mutation signatures are indicated at the bottom. (b) Alterations encoded by recurrent mutations in the NOTCH1 and NOTCH2 genes. Protein domains and mutated residues are color-coded and depicted at the top. At the bottom left, multispecies conservation of the Phe357 mutation hotspot in EGF-like domain 9 is shown. At the bottom right, the Phe357 residue is mapped onto a crystal structure of NOTCH1 EGFlike domain 13 (Protein Data Bank (PDB), 2VJ3). The wild-type residue is shown in red, and the p.Phe357Ser missense alteration is shown in magenta. EGF, EGF-like domain; EGF (Ca 2+ ), Ca 2+ -binding EGF-like domain; LNR, Lin12/Notch repeat; HD, heterodimerization domain; TM, transmembrane domain; ANK, ankyrin repeat; PEST, proline, glutamic acid, serine, threonine-rich degradation motif. (c) Overall pattern of CNAs. The vertical axis represents the genome. The horizontal axis indicates the frequency of chromosomal deletions (blue) or copy-neutral LOH events (green), as well as amplifications (red). Consensus cancer-related genes located within corresponding genomic regions are indicated. (d) Association of CNAs with cell of origin. The horizontal axis represents association significance, calculated using two-sided Fisher's exact test. The dashed line corresponds to a q value of 0.1. The colored bars represent association odds ratios (green, enriched in oligodendroglial tumors; brown, enriched in astrocytic tumors).
npg l e t t e r s Similarly, amplification of the MYC oncogene (8q) (26%; q = 1.0) was observed in both subtypes (Fig. 1c,d and Supplementary Fig. 4) .
Next, to identify genomic alterations that drive IDH1-mutant glioma progression, we compared progressed tumors with their corresponding lower-grade counterparts with respect to mutations and CNAs (Figs. 2 and 3) . Excluding three hypermutated tumors, gliomas acquired a median of 21 protein-altering mutations as they progressed (Fig. 2a) . Notably, although on average 27% of the mutations and 30% of the CNAs present in the initial tumors were no longer detected during progression, the recurrent IDH1 mutation affecting Arg132 was never lost during progression and remained clonal in all progressed tumors 6, 17 (Fig. 2 and Supplementary  Fig. 5 ). Mutations acquired during progression also showed significantly different trinucleotide signatures from those that were lost (P = 0.05 and 1.0 × 10 −5 for non-hypermutated and hypermutated samples, respectively, two-sided χ 2 test) (Supplementary Fig. 6 ). Furthermore, during progression, 27% of the higher-grade gliomas acquired different coding mutations in the same glioma driver genes, such as TP53, ATRX, CIC and FUBP1, in which mutations were observed in their lower-grade counterparts 6, 17 ( Fig. 2c and Supplementary Fig. 5 ). These findings suggest that genomic heterogeneity, which is known to occur in gliomas, has a substantial role during progression 6, 17 . Although patients who underwent adjunct therapy after initial diagnosis, such as chemotherapy and/ or radiation therapy, tended to acquire more mutations upon progression than patients who did not (P = 2.1 × 10 −3 , two-sided Wilcoxon rank-sum test), the patterns of CNAs remained the same (Supplementary Fig. 7) .
During glioma progression, the receptor tyrosine kinase (RTK)-RAS-phosphoinositide 3-kinase (PI3K) pathway, the NOTCH pathway and FAT receptors were most frequently altered (in 22%, 12% and 10% of the patients, respectively) (Fig. 3a) . Genes involved in epigenetic patterning, including histone modifiers and components of the SWI/SNF chromatin-remodeling complex (44% and 5%, npg l e t t e r s respectively), as well as genes involved in transcriptional modulation (12%), were also mutated [18] [19] [20] [21] [22] [23] (Fig. 3a) .
The most frequently amplified genomic region during progression was the MYC locus on chromosome 8q (22% of patients), and amplification was significantly associated with progression (q = 1.7 × 10 −3 , likelihood-ratio test) (Fig. 3b,c) . We also observed additional genomic alterations that could potentially activate the MYC pathway, including deletions affecting the FBXW7 gene, a MYC suppressor located on chromosome 4q (29% of patients; q = 6.2 × 10 −4 ), as well as the MAX gene, encoding a MYC-associated factor and tumor suppressor, located on 14q (24%; q = 9.5 × 10 −4 ) 24 (Fig. 3b,c) . In addition to MYC-related loci, the FOXM1 gene locus on 12p was amplified in 20% of patients, and amplification was significantly associated with progression (q = 2.7 × 10 −3 ) (Fig. 3b,c) . The most commonly deleted region during progression was chromosome 9p, encompassing the CDKN2A-CDKN2B locus (61%; q = 1.1 × 10 −7 ) (Fig. 3b,c) . PTEN (10q) was also frequently deleted (39%), and deletion was associated strongly with tumor progression (q = 6.2 × 10 −4 ) (Fig. 3b,c) . Chromosome 10q deletion has previously been identified as a marker for poor prognosis in low-grade gliomas 25 . Finally, we observed deletions affecting the FAT receptor genes FAT1 (4q; 34%; q = 3.9 × 10 −3 ) and FAT2 (5q; 29%; q = 6.8 × 10 −4 ) (Fig. 3b,c) .
To characterize transcriptional changes during progression, we compared the gene expression profiles of the progressed gliomas with the profiles of their corresponding initial tumors (n = 28 pairs) (Fig. 4) . Gene set enrichment analysis (GSEA) as well as analysis of differential gene expression indicated that cell cycle processes, including the FOXM1 and E2F transcription factor networks and the MYC signaling pathway, were enriched ( Fig. 4 and Supplementary Figs. 8  and 9 ). This finding is consistent with the observation that genomic loci harboring several pathway components were themselves altered through CNAs during progression (Fig. 3b,c) . Among these pathways, both the FOXM1 and E2F networks have important roles in promoting G1/S cell cycle transition, with the former also being a key regulator of the G2/M transition, acting synergistically with MYC signaling [26] [27] [28] [29] [30] [31] [32] . Besides being a major determinant of mitotic cell fate and a transcriptional amplifier, MYC is also required for the maintenance of glioma stem cells [32] [33] [34] [35] [36] . Indeed, genes important for stem cell identity were upregulated during progression (Fig. 4) . Differentially downregulated genes included genes that function in the neuronal system (q = 1.1 × 10 −24 , hypergeometric test) and genes that are targets of Polycomb repressive complex 2 (PRC2) in human embryonic stem cells (hESCs) (q = 1.4 × 10 −11 ) (Fig. 4b) .
We next compared the DNA methylation profiles of progressed gliomas with the profiles of their corresponding initial tumors (n = 24 pairs), correlating methylation and gene expression changes (Fig. 5) . Interestingly, whereas the overall methylation level decreased during progression (P = 2.6 × 10 −3 , paired two-sided Student's t test), a small fraction (0.6%) of the 307,250 CpG sites measured became significantly hypermethylated ( Fig. 5a and Supplementary Figs. 10 and 11). To understand the biological functions associated with these hypermethylated CpGs, we performed genomic region enrichment analysis, identifying enrichment for key developmental transcription factor families (q = 4.4 × 10 −225 , hypergeometric test), including homeotic genes in all four of the HOX clusters, as well as large subsets of the FOX, PAX, NKX, SOX, TALE, TALX and TBX family genes 37 ( Supplementary Fig. 12 ). These transcription factors regulate a wide variety of developmental processes, including pattern formation, cell fate specification and neurogenesis. In addition, hypermethylated CpGs were also enriched in promoters marked by histone H3 lysine 27 trimethylation (H3K27me3) in hESCs (q = 4.1 × 10 −234 , hypergeometric test) as well as PRC2 targets in hESCs (q = 7.4 × 10 −204 ) (Fig. 5a) . Indeed, by aggregating Encyclopedia of DNA Elements (ENCODE) hESC H3K27me3 chromatin immunoprecipitation and npg l e t t e r s sequencing (ChIP-seq) data, we observed enhanced H3K27me3 signal around CpGs that became hypermethylated during glioma progression 38 ( Fig. 5b) . We obtained similar results using the ChIP-seq hESC data sets for EZH2 and SUZ12 (subunits of PRC2) 38 ( Fig.  5b) . Notably, acquisition of DNA hypermethylation at PRC2 target genes in hESCs has been previously observed in colorectal, ovarian and breast cancers [39] [40] [41] . The observed changes in DNA methylation correlated with alterations in gene expression (Supplementary Fig. 13 ). Namely, PRC2 target genes in hESCs that became hypermethylated were also transcriptionally downregulated during progression (Figs. 4b and 5a, and Supplementary Fig. 13 ). When we restricted our analysis to CpGs located at promoter regions instead of considering all CpGs, we observed similar correlations (Supplementary Fig. 14) .
In hESCs, PRC2 binds to the promoters of key developmental transcription factor genes and deposits repressive H3K27me3 marks, thereby maintaining stem cell identity 41 (Fig. 5c) . Our observations suggest that, during glioma progression, genes that are bound by l e t t e r s PRC2 in hESCs become further hypermethylated, replacing reversible gene repression with permanent silencing, which in turn could 'lock' glioma cells into a perpetual state of self-renewal [39] [40] [41] (Fig. 5c) . Furthermore, in 65% of the patients, we also identified increased expression (log 2 (fold change) >0.5) of the catalytic subunit of PRC2, EZH2 (q = 2 × 10 −4 , paired two-sided moderated Student's t test) during progression (Fig. 5d) . EZH2 is known to interact with DNA methyltransferases, associating with their aberrant activities in prostate cancer 42, 43 . By combining mutation, CNA, and gene expression and DNA methylation alteration data, we were able to uncover oncogenic pathways that drive glioma progression (Fig. 6a) . The MYC signaling pathway became activated in 56% of the patients and showed one of the strongest associations with progression (q = 8.2 × 10 −8 , likelihood-ratio test) (Fig. 6a,b) . As mentioned above, alterations in the individual MYC signaling components MYC, FBXW7 and MAX were each independently associated with progression (q < 1.0 × 10 −3 for each) (Fig. 3b,c) . Additionally, the RTK-RAS-PI3K pathway and FAT receptors were altered in 68% and 54% of the patients, respectively (q = 1.8 × 10 −5 for both), regardless of whether patients had received adjunct treatment, except for a weak association of RTK-RAS-PI3K pathway activation with treatment (q = 0.05, Fisher's exact test) (Fig. 6a,b and Supplementary Fig. 7 ). This observation suggests that alterations in these pathways are not driven by adjunct therapy but instead reflect genomic changes that underlie glioma progression. Downstream of the MYC and RTK-RAS-PI3K signaling pathways, genes involved in cell cycle regulation were altered in nearly all of the patients (88%; q = 1.6 × 10 −9 , likelihood-ratio test) (Fig. 6a,b) . Further downstream, the FOXM1 and E2F2 networks were upregulated in 85% and 73% of the patients, respectively, promoting G2/M and G1/S transitions (Fig. 6a) . Upregulation of EZH2, observed in 65% of patients, could also lead to aberrant crosstalk with DNA methyltransferases, which in turn is linked to hypermethylation of developmental transcription factors required for differentiation, as observed in 75% of patients, reprogramming glioma cells into an hESC-like state (Fig. 6a) .
Having identified oncogenic pathways driving IDH1-mutant glioma progression and taking into account previous studies indicating the therapeutic potential of BET inhibition in primary GBMs, we tested the sensitivity of IDH1-mutant glioma cells to two BET inhibitors, the well-established JQ1 compound and GS-626510, a novel inhibitor [44] [45] [46] [47] . Using six patient-derived IDH1-mutant primary glioma cultures, as well as a well-characterized IDH1-mutant glioma cell line, we observed high sensitivity of IDH1-mutant cells to both BET inhibitors in vitro, with half-maximal inhibitory concentration (IC 50 ) values less than 250 nM and achieving maximum cell death of 31 to 77% (ref. 48) (Fig. 6c and Supplementary Table 3) . Although previous studies have reported BET inhibition to target MYC signaling in hematopoietic malignancies, further studies will be needed to identify the exact therapeutic target of BET inhibition as well as the effectiveness of this inhibition in vivo in gliomas 46, 47, 49 .
In summary, through direct comparison of the genomic landscape of progressed gliomas with that of their corresponding lower-grade counterparts, we identified a plethora of convergent alterations, including activation of the MYC and RTK-RAS-PI3K signaling pathways, alterations in cell cycle regulators such as CDKN2A-CDKN2B, upregulation of the FOXM1-and E2F2-mediated cell cycle transitions, and epigenetic silencing of key developmental transcription factors. Overall, our observations suggest that these pathways converge upon opposing but synergistic cellular effects that stimulate proliferation while inhibiting differentiation during glioma progression. In addition to dissecting these fundamental molecular mechanisms underlying IDH1-mutant glioma malignant progression, our results further suggest BET inhibition as a potential therapeutic approach. 
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Tumor sample acquisition and quality control. Tumor samples and clinical information used in this study were obtained under informed consent and approval of the institutional review board of the University of Bonn Medical School, the University Hospital of Cologne and the Acıbadem University School of Medicine. Clinical information is shown in Supplementary Table 1. All tumor samples were collected during surgical resection and were either snap frozen or formalin fixed and paraffin embedded. Sections stained with hematoxylin and eosin or formalin-fixed, paraffin-embedded tissues were reviewed again by neuropathologists at Yale University to confirm the clinical diagnosis and to assess percentage of tumor nuclei and percentage of necrosis. For samples with a low percentage of tumor nuclei or a high percentage of necrosis, tumor regions were isolated using laser-capture microdissection.
DNA, RNA and protein extraction. Frozen tissues were first homogenized using the QIAShredder (Qiagen, 79656). Tumor DNA, RNA and protein samples were subsequently extracted using the AllPrep DNA/RNA/Protein Mini kit (Qiagen, 80004). For formalin-fixed, paraffin-embedded tissues, tumor DNA was extracted using the BiOstic FFPE Tissue DNA Isolation kit (MO BIO Laboratories, 12250-50). Extracted DNA was repaired using BioLabs PreCR Repair Mix (New England BioLabs, M0309S) with human alkyladenine DNA glycosylase (hAAG) (New England BioLabs, M0313S). Repaired DNA was subsequently purified using the QIAquick Nucleotide Removal kit (Qiagen, 28304). Normal blood DNA samples were extracted from patientmatched peripheral blood mononuclear cells using the QIAamp DNA Blood Mini kit (Qiagen, 51104).
Whole-exome sequencing and mutation calling. Exome capture was performed using NimbleGen SeqCap EZ Human Exome Library v2.0 (Roche NimbleGen, 05860504001), following the manufacture's protocol with modifications, as described previously 50 . The library was sequenced on Illumina HiSeq 2000 or 2500 instruments using 74-bp paired-end reads. Sequencing reads were evaluated using the FASTX-Toolkit and trimmed using cutadapt (version 1.2.1) to remove low-quality 3′-end bases and PCR primercontaminated sequences 51 . Preprocessed paired-end reads were aligned to the human reference genome (GRCh37) using Stampy (version 1.0.21) in a hybrid mode with Burrows-Wheeler Aligner (BWA; version 0.5.9-r16) 52, 53 . All aligned reads were subsequently processed using both the Picard suite (version 1.86) and the Genome Analysis Toolkit (GATK; version 2.5-2), including deduplication, alignment quality assessment, multisequence local realignment and base quality recalibration 54 . Quality control metrics are shown in Supplementary Table 2 .
Mutation calling was performed using the GATK HaplotypeCaller tool for tumor samples with matching normal DNA samples and the UnifiedGenotyper tool for tumor samples without matching normal samples 54 . For blood-matched tumor samples, genotype likelihood-based somatic scores were also calculated 55 . Detected variants were annotated on the basis of Ensembl annotations (version 69) using Variant Effect Predictor (VEP; version 2.7) 56 . Variants were filtered on the basis of allelic and overall depths of coverage, strand bias, somatic score, mapping quality and coverage-adjusted variant quality, as well as location within repeat or segmental duplicated regions, as described previously 57, 58 . Variants with overall alternate allele frequency >0.01 in the 1000 Genome Project database or in the National Heart, Lung, and Blood Institute (NHLBI) Exome Variant Server (ESP6500SI-V2) database were also excluded 59 . Variants detected in >4 individuals in the Exome Aggregation Consortium database (ExAC; release 0.3) or mapping to genes with >100 conserved alleles in an internal database of over 2,000 exomes were excluded as well. Additionally, consensus oncogenic genes and variants were identified on the basis of the Catalogue of Somatic Mutations in Cancer (COSMIC) database 60 . Lastly, for tumor samples without matched normal DNA samples, variants detected in >2 individuals in the ExAC database, unless also reported in the COSMIC database, were excluded 60 . All detected mutations are shown in Supplementary Table 4. Validation of mutations identified by whole-exome sequencing. To confirm mutations identified by exome sequencing, we made use of either Sanger sequencing or high-throughput sequencing of the NimbleGen SeqCap EZ Comprehensive Cancer Design (Roche NimbleGen, 4000007080), which captures 578 cancer genes. High-throughput sequencing was performed on an Illumina HiSeq 2500 instrument, reaching 617-fold coverage on average. Read alignment and mutation calling were performed using the GATK 'best-practices' pipeline 54, 61 . Detected mutations were annotated using ANNOVAR (version 2015Mar22) 62 . Sequencing quality control metrics as well as results are shown in Supplementary Tables 5 and 6. For Sanger sequencing, target genomic DNA encompassing mutations was PCR amplified. We also tested recurrent TERT promoter mutations in 16 tumor pairs [6] [7] [8] . Amplicons were cycle sequenced on Applied Biosystems 9800 Fast Thermal Cyclers and analyzed on an Applied Biosystems 3730xl DNA Analyzer. Primer sequences as well as the results of the Sanger sequencing are shown in Supplementary Table 7 . The results of mutation validation are summarized in Supplementary Table 8 .
Trinucleotide mutation signatures. Each single-nucleotide substitution was categorized into one of 96 possible trinucleotide mutations, C>A/G>T, C>G/G>C, C>T/G>A, T>A/A>T, T>C/A>G or T>G/A>C, taking into account the bases immediately 5′ and 3′ to each substitution. Patterns of trinucleotide signatures for mutations specific to progressed tumors were compared to those of mutations specific to initial tumors by two-sided χ 2 test with 100,000 simulations.
Copy number analysis and tumor purity estimation. For all samples, the whole-exome sequencing read depth was calculated for each captured target region. For 43 glioma DNA samples and 15 blood DNA samples, genome-wide SNP array analysis was also performed using the HumanOmniExpress-24 v1.1 BeadChip (Illumina, WG-315-1101), following the manufacturer's instructions. CNAs were detected on the basis of either sequencing depth estimates or SNP array signal intensities using circular binary segmentation (CBS) as implemented in the DNAcopy package in R. For each CNA segment, the minor allele frequency (MAF) was calculated to exclude false positive CNA events. On the basis of MAF within deleted chromosomal regions, tumor purity was also estimated using the qpure package in R (ref. 63) . By chromosomal amplifications and deletions, we refer to copy number gains and losses, respectively, of any length and amplitude 64 . Lastly, consensus cancer-related genes within each CNA were identified on the basis of the COSMIC database 60 .
Validation of MYC copy number by genomic DNA quantitative PCR. MYC gene copy number was assessed in 24 randomly selected glioma samples by quantitative PCR (qPCR), using the Applied Biosystems 7900HT Fast Real-Time PCR System with iQ SYBR Green Supermix (Bio-Rad, 1708880). Copy number of the ZNF423 locus, a region with normal copy number, was assessed as well. Additionally, to determine the qPCR threshold cycle, copy number in female reference DNA (Promega, G1521) in four serial dilutions was also measured. All reactions were run in triplicate. For each sample, the copy number of MYC was calculated and normalized to that of ZNF423. Primer sequences and results are shown in Supplementary Figure 4c. Mutation clonal frequency estimation. Each mutation's clonal frequencythe fraction of tumor cells carrying the mutation-was estimated on the basis of its mutant allele frequency, taking into account the chromosomal copy number at the mutation site, as well as tumor purity, as described previously 65 . We considered a mutation to be specific to the progressed tumor if there were no mutant reads in the paired initial tumor and vice versa.
Association of gene alterations with cell of origin. Association of 28 recurrent CNAs with cell of origin was investigated by two-sided Fisher's exact test. Multiple testing was corrected for using the Benjamini-Hochberg method; q < 0.1 was considered significant. In addition, we considered an event to be enriched in astrocytic tumors, as opposed to oligodendroglial ones, if the odds ratio was larger than 1 and vice versa.
Association of gene alterations with glioma progression. For 29 recurrent CNAs, we tested the statistical association of each with progression using conditional logistic regression, matching initial and progressed tumors from the same patient. Likelihood-ratio test P values were calculated using the clogit function in the survival package in R and were corrected for multiple testing using the Benjamini-Hochberg method; CNAs with q < 0.1 were considered significant 66 . Using a similar approach, we tested the association of pathways npg with progression, by first grouping 77 genes into ten categories on the basis of the pathways to which they belong.
Statistical relationships between gene alterations during glioma progression.
We tested the statistical relationships among 42 genes altered through mutation and/or CNA during progression. The results are shown in Supplementary Figure 15 .
Pairwise co-occurrence and mutual exclusivity. For every gene pair, we performed a Fisher's exact test to discover co-occurring or mutually exclusive relationships. We tested for these relationships using genomic alterations acquired during progression. Gene pairs with nominal P < 0.05 were considered co-occurring or mutually exclusive and were excluded from the following bivariate conditional logistic regression analysis.
Two-gene models. For every gene pair, we tested whether one gene contributed independently to progression by conditioning on the other gene. Specifically, we performed bivariate conditional logistic regression without an interaction term. Likelihood-ratio test P values were calculated using the clogit function in R and were corrected for multiple testing using the BenjaminiHochberg method 66 . For each gene pair, if both genes showed q < 0.1, we considered them to each independently contribute to progression, whereas, if only one gene showed q < 0.1, we considered this gene to have 'masked' the effect of the other gene.
Gene expression analysis. High-quality RNA (RNA integrity number (RIN) ≥7.5) from 62 exome-sequenced glioma samples (28 initial-progressed tumor pairs plus three initial and three progressed tumors) was used for gene expression array analysis, on the HumanHT-12 v4 Expression BeadChip (Illumina, BD-103-0204). Gene expression data were processed using the limma and sva packages in R, including background correction, quantile normalization and batch effect removal 67, 68 . After excluding undetected microarray probes (detection P > 0.05 in over 90% of the samples), a total of 18,416 probes, representing 16,202 genes, remained.
Consensus clustering and multidimensional scaling. The top 1,000 probes showing large variation, as measured by standard deviation, across the data set were selected for consensus clustering and multidimensional scaling (MDS). Consensus clustering was performed using a hierarchical clustering method based on the Pearson correlation coefficients of the selected probes, using the ConsensusClusterPlus package in R (ref. 69) . MDS was performed using the R command cmdscale on the Euclidean distances of the selected probes. The results are shown in Supplementary Figure 16 .
Gene set enrichment analysis. GSEA was conducted using the GSA package in R with the Molecular Signatures Database (MSigDB; version 5.0) c2 gene set collection 70, 71 . Empirical P values of enrichment were calculated by 100,000 gene set permutations 70, 71 . FDRs were also estimated 70, 71 .
Differential expression analysis. Differentially expressed genes were identified by comparing the expression profiles of 28 progressed tumors with the profiles of their corresponding initial tumors, using linear models and empirical Bayes methods, as implemented in the limma package in R (ref. 72) . Gene significance was determined on the basis of logarithm of odds (LOD) scores, as well as P values calculated by paired two-sided moderated Student's t test, corrected for multiple testing using the Benjamini-Hochberg method (Supplementary Table 9 ) 72 . Functional enrichment of differentially expressed genes was determined using the hypergeometric test in R with the MSigDB c2 gene sets 70 . Multiple testing was adjusted for using the Benjamini-Hochberg method. Gene interaction networks were constructed using the ReactomeFI plugin (version 4.1.1.beta) in Cytoscape (version 3.0.1) 73, 74 . FDRs for identified interaction networks were also calculated using ReactomeFI 73, 74 .
Co-expression network analysis. A co-expression network was constructed on the basis of the pairwise Pearson correlation coefficients of all genes, using the WGCNA package in R (ref. 75 ). Modules of highly correlated genes in gliomas were identified 75 . The first principal component of each module, also known as the module eigengene, was calculated 75 . Association of module eigengenes with glioma progression or with cell of origin was assessed using paired and unpaired two-sided Student's t tests, respectively, to identify relevant gene clusters 75 . The results are shown in Supplementary Figure 17. RT-qPCR validation of gene expression microarrays. RNA from eight randomly selected initial-progressed glioma pairs was reverse transcribed using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific, 18080044). qPCR was performed using the Applied Biosystems 7900HT Fast Real-Time PCR System with iQ SYBR Green Supermix. Primer sequences are shown in Supplementary Table 10 . Each primer pair had three technical replicates per tumor sample. Fold change in mRNA levels during progression was calculated and normalized to the level of ACTB. P values were calculated by two-sided Wilcoxon rank-sum test, with a null distribution of zero. The results are shown in Supplementary Figure 18. DNA methylation analysis. Genome-wide DNA methylation profiling was performed on 48 glioma samples (24 initial-progressed tumor pairs) using the Infinium HumanMethylation450 BeadChip (Illumina, WG-314-1003). Generated raw intensity (idat) files were converted into R software-compatible format using the methylumi package 76 . DNA methylation sites with missing values, located within repeat regions or on sex chromosomes were excluded. Probes containing common SNPs were also filtered out, with a total of 307,250 probes retained. Methylation data were subsequently converted into β values, ranging from 0 (unmethylated) to 1 (fully methylated), and these values were normalized using a beta-mixture quantile normalization method (BMIQ) 77 .
Consensus clustering and multidimensional scaling. The top 12,000 most variable probes were selected and analyzed using the same methods as with gene expression data. The results are shown in Supplementary Figure 19 .
Differential CpG methylation analysis. Differentially methylated CpGs were identified by comparing the methylation profiles of 24 progressed tumors with the profiles of their corresponding initial tumors, using the same methods as with differential gene expression analysis 72, 78 . The results are shown in Supplementary Table 11 . Analysis of functional enrichment of differentially methylated CpGs was performed using the Genomic Regions Enrichment of Annotations Tool (GREAT), taking all 307,250 methylation sites as the background 37 .
Analysis of differential promoter methylation. Promoter CpGs were defined as CpGs no more than 200 bp upstream of transcription start sites. For genes with more than one promoter CpG, mean β values were calculated 78 . The results are shown in Supplementary Table 12 . Functional enrichment was determined using the MSigDB c2 gene sets, as with differential gene expression analysis 70 .
Gene-level correlation of promoter methylation with gene expression. For each gene, promoter methylation alterations during progression were correlated with downstream gene expression changes (n = 22 tumor pairs). Spearman's correlation coefficients (ρ), as well as P values, were calculated. Multiple testing was adjusted for using the Benjamini-Hochberg method. The results are shown in Supplementary Figure 20 .
Human embryonic stem cell ChIP-seq signal aggregation. hESC (H1-hESC) H3K27me3, EZH2 and SUZ12 ChIP-seq data (bigwig files) were downloaded from the ENCODE data portal 38 . Average ChIP-seq signals surrounding hypermethylated, hypomethylated and all remaining DNA methylation sites were calculated using the Cis-Regulatory Element Annotation System (CEAS) 79 .
Survival analysis of the TCGA cohort. Genetic and clinical data for grade II and III gliomas in The Cancer Genome Atlas (TCGA) cohort were accessed through the cBioPortal for Cancer Genomics 7, 80, 81 . Grade II and III gliomas carrying IDH1 mutations affecting Arg132 (n = 219) were selected. Using cBioPortal, we generated Kaplan-Meier curves, comparing overall survival rates in patients with and without genetic alterations of interest 80, 81 . Log-rank test P values were also calculated 80, 81 . The results are shown in Supplementary Figure 21. Pharmacological inhibition of glioma cell growth. Glioma cultures were derived from tumor samples different from the whole exome-sequenced samples. This was because the paired tumors were obtained from international collaborators in Germany and Turkey, who collected the samples from 6 to 27 years ago. Because viable cultures could not be established from these patients, we instead derived glioma cell cultures from freshly resected glioma tissues at the Yale-New Haven Hospital. In addition, TS-603 and TS-667, previously npg
